EP3134078A1 - Acne solution - Google Patents
Acne solutionInfo
- Publication number
- EP3134078A1 EP3134078A1 EP15782917.7A EP15782917A EP3134078A1 EP 3134078 A1 EP3134078 A1 EP 3134078A1 EP 15782917 A EP15782917 A EP 15782917A EP 3134078 A1 EP3134078 A1 EP 3134078A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mixture
- percent
- bakuchiol
- retinol
- bisabolol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010000496 acne Diseases 0.000 title abstract description 88
- 208000002874 Acne Vulgaris Diseases 0.000 title abstract description 83
- 239000000203 mixture Substances 0.000 claims abstract description 339
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims abstract description 148
- LFYJSSARVMHQJB-UHFFFAOYSA-N Backuchiol Natural products CC(C)=CCCC(C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-UHFFFAOYSA-N 0.000 claims abstract description 112
- LFYJSSARVMHQJB-GOSISDBHSA-N bakuchinol Natural products CC(C)=CCC[C@@](C)(C=C)C=CC1=CC=C(O)C=C1 LFYJSSARVMHQJB-GOSISDBHSA-N 0.000 claims abstract description 112
- LFYJSSARVMHQJB-QIXNEVBVSA-N bakuchiol Chemical compound CC(C)=CCC[C@@](C)(C=C)\C=C\C1=CC=C(O)C=C1 LFYJSSARVMHQJB-QIXNEVBVSA-N 0.000 claims abstract description 112
- 229940117895 bakuchiol Drugs 0.000 claims abstract description 112
- KXXXNMZPAJTCQY-UHFFFAOYSA-N bakuchiol Natural products CC(C)CCCC(C)(C=C)C=Cc1ccc(O)cc1 KXXXNMZPAJTCQY-UHFFFAOYSA-N 0.000 claims abstract description 112
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 83
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 81
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 81
- 229940036350 bisabolol Drugs 0.000 claims abstract description 81
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 81
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims abstract description 78
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims abstract description 74
- 229960003471 retinol Drugs 0.000 claims abstract description 74
- 235000020944 retinol Nutrition 0.000 claims abstract description 74
- 239000011607 retinol Substances 0.000 claims abstract description 74
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims abstract description 64
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 58
- 239000004342 Benzoyl peroxide Substances 0.000 claims abstract description 51
- 244000226566 Psoralea corylifolia Species 0.000 claims abstract description 51
- 235000019400 benzoyl peroxide Nutrition 0.000 claims abstract description 51
- 229960003328 benzoyl peroxide Drugs 0.000 claims abstract description 48
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229960004889 salicylic acid Drugs 0.000 claims abstract description 39
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims abstract description 32
- 229960001727 tretinoin Drugs 0.000 claims abstract description 32
- OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229960000565 tazarotene Drugs 0.000 claims abstract description 29
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 27
- 239000004094 surface-active agent Substances 0.000 claims abstract description 24
- 230000003115 biocidal effect Effects 0.000 claims abstract description 23
- 239000000284 extract Substances 0.000 claims description 76
- 238000002156 mixing Methods 0.000 claims description 42
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 39
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 39
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 39
- 229940068977 polysorbate 20 Drugs 0.000 claims description 39
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 20
- 239000008367 deionised water Substances 0.000 claims description 15
- 229910021641 deionized water Inorganic materials 0.000 claims description 15
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 14
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 claims description 13
- 230000003255 anti-acne Effects 0.000 claims description 13
- 229940073499 decyl glucoside Drugs 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
- 240000007817 Olea europaea Species 0.000 claims description 11
- 244000124853 Perilla frutescens Species 0.000 claims description 10
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 229960002227 clindamycin Drugs 0.000 claims description 10
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 claims description 10
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 claims description 10
- 229940073507 cocamidopropyl betaine Drugs 0.000 claims description 10
- 229960003276 erythromycin Drugs 0.000 claims description 10
- 239000011148 porous material Substances 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 230000003381 solubilizing effect Effects 0.000 claims description 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 7
- 235000002725 Olea europaea Nutrition 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 235000004348 Perilla frutescens Nutrition 0.000 claims description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 6
- 239000004299 sodium benzoate Substances 0.000 claims description 6
- 235000010234 sodium benzoate Nutrition 0.000 claims description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 5
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 5
- 239000000470 constituent Substances 0.000 claims description 5
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 5
- 230000000845 anti-microbial effect Effects 0.000 claims description 4
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 3
- FQCSIUSICFAMDD-UHFFFAOYSA-N 2-oxopyrrolidine-1-carboxylic acid;sodium Chemical compound [Na].OC(=O)N1CCCC1=O FQCSIUSICFAMDD-UHFFFAOYSA-N 0.000 claims description 2
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 2
- 229940079889 pyrrolidonecarboxylic acid Drugs 0.000 claims description 2
- BDOYKFSQFYNPKF-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;sodium Chemical compound [Na].[Na].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O BDOYKFSQFYNPKF-UHFFFAOYSA-N 0.000 claims 1
- 239000004615 ingredient Substances 0.000 abstract description 66
- 238000011282 treatment Methods 0.000 abstract description 21
- 239000004480 active ingredient Substances 0.000 abstract description 14
- 238000002360 preparation method Methods 0.000 abstract description 11
- 230000000699 topical effect Effects 0.000 abstract description 4
- 230000008569 process Effects 0.000 abstract description 3
- 229920000136 polysorbate Polymers 0.000 abstract description 2
- 229950008882 polysorbate Drugs 0.000 abstract description 2
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 238000012545 processing Methods 0.000 description 33
- 239000000047 product Substances 0.000 description 28
- 239000000499 gel Substances 0.000 description 27
- 150000001875 compounds Chemical class 0.000 description 23
- 238000004519 manufacturing process Methods 0.000 description 23
- 230000002209 hydrophobic effect Effects 0.000 description 22
- 238000009472 formulation Methods 0.000 description 18
- 239000003921 oil Substances 0.000 description 17
- 239000000243 solution Substances 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 13
- -1 retinoids Substances 0.000 description 11
- 229940088710 antibiotic agent Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000003902 lesion Effects 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 230000002757 inflammatory effect Effects 0.000 description 9
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 8
- 241000580938 Sapindus Species 0.000 description 8
- 229940100524 ethylhexylglycerin Drugs 0.000 description 8
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 235000011399 aloe vera Nutrition 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 239000003599 detergent Substances 0.000 description 7
- 239000000839 emulsion Substances 0.000 description 7
- 239000002085 irritant Substances 0.000 description 7
- 239000006210 lotion Substances 0.000 description 7
- 229940094546 ppg-2 isoceteth-20 acetate Drugs 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 244000144927 Aloe barbadensis Species 0.000 description 5
- 235000002961 Aloe barbadensis Nutrition 0.000 description 5
- 206010013786 Dry skin Diseases 0.000 description 5
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 5
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 5
- 229940061720 alpha hydroxy acid Drugs 0.000 description 5
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 5
- 230000003750 conditioning effect Effects 0.000 description 5
- 230000037336 dry skin Effects 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 150000002634 lipophilic molecules Chemical class 0.000 description 5
- 230000037390 scarring Effects 0.000 description 5
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 4
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 4
- 206010033733 Papule Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000996 additive effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000003974 emollient agent Substances 0.000 description 4
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- PHOQVHQSTUBQQK-SQOUGZDYSA-N D-glucono-1,5-lactone Chemical compound OC[C@H]1OC(=O)[C@H](O)[C@@H](O)[C@@H]1O PHOQVHQSTUBQQK-SQOUGZDYSA-N 0.000 description 3
- 239000004375 Dextrin Substances 0.000 description 3
- 229920001353 Dextrin Polymers 0.000 description 3
- 241001446509 Psoralea Species 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 239000004098 Tetracycline Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000019425 dextrin Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000012209 glucono delta-lactone Nutrition 0.000 description 3
- 229960003681 gluconolactone Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000007794 irritation Effects 0.000 description 3
- 239000003410 keratolytic agent Substances 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 229960002180 tetracycline Drugs 0.000 description 3
- 229930101283 tetracycline Natural products 0.000 description 3
- 235000019364 tetracycline Nutrition 0.000 description 3
- 150000003522 tetracyclines Chemical class 0.000 description 3
- 239000003860 topical agent Substances 0.000 description 3
- 239000000230 xanthan gum Substances 0.000 description 3
- 235000010493 xanthan gum Nutrition 0.000 description 3
- 229920001285 xanthan gum Polymers 0.000 description 3
- 229940082509 xanthan gum Drugs 0.000 description 3
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 241001116389 Aloe Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 244000042664 Matricaria chamomilla Species 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 206010040844 Skin exfoliation Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000002138 bisabolol group Chemical group 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000031513 cyst Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 2
- 229940051250 hexylene glycol Drugs 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000005414 inactive ingredient Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- 239000007764 o/w emulsion Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000007762 w/o emulsion Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GTJOHISYCKPIMT-UHFFFAOYSA-N 2-methylundecane Chemical compound CCCCCCCCCC(C)C GTJOHISYCKPIMT-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- SGVYKUFIHHTIFL-UHFFFAOYSA-N Isobutylhexyl Natural products CCCCCCCC(C)C SGVYKUFIHHTIFL-UHFFFAOYSA-N 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 244000062730 Melissa officinalis Species 0.000 description 1
- 235000010654 Melissa officinalis Nutrition 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 244000179750 Psoralea glandulosa Species 0.000 description 1
- 235000017667 Psoralea glandulosa Nutrition 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000001140 aloe barbadensis leaf extract Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002280 anti-androgenic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000000498 cooling water Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000011810 insulating material Substances 0.000 description 1
- VKPSKYDESGTTFR-UHFFFAOYSA-N isododecane Natural products CC(C)(C)CC(C)CC(C)(C)C VKPSKYDESGTTFR-UHFFFAOYSA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229930003811 natural phenol Natural products 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000000820 nonprescription drug Substances 0.000 description 1
- 231100000404 nontoxic agent Toxicity 0.000 description 1
- HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- ZZPKZRHERLGEKA-UHFFFAOYSA-N resorcinol monoacetate Chemical compound CC(=O)OC1=CC=CC(O)=C1 ZZPKZRHERLGEKA-UHFFFAOYSA-N 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940042129 topical gel Drugs 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/487—Psoralea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/535—Perilla (beefsteak plant)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Definitions
- the invention relates to the field of skincare compositions and more specifically to compositions for treating acne vulgaris.
- Acne vulgaris is a chronic inflammatory condition of the pilosebaceous units of the skin, which is particularly prevalent in adolescents.
- the condition generally causes the formation, on the skin, of comedones, red papules, pustules and sometimes cysts. This is unsightly and furthermore, if untreated, acne can lead to scarring of the skin.
- the major causes of acne are thought to be an increase in sebum production, an increased presence of proprionibacterium acnes (P. acne), blockage of the pilosebaceus duct and the production of inflammation.
- Typical treatments for acne include therapies containing benzoyl peroxide, retinoids or a combination of an antibiotic and benzoyl peroxide.
- these therapies are harsh on the skin and can cause excessive dryness, redness, irritation, and peeling.
- These therapies can take between 3 to 6 weeks to reduce inflammatory acne lesions by fifty percent. The amount of time its takes for typical acne treatment products to work and the tolerability issues they present, cause users to be noncompliant in using these products as prescribed;
- a composition and process of preparation of a compound is for the treatment of acne.
- the compound is for topical application to the skin.
- the composition includes Bakutrol(TM), containing the ingredient bakuchiol, that is solubilized in a water-based solution.
- a composition includes hydrolyzed psoralea corylifolia containing bakuchiol as a primary component (or Bakutrol), and bisabolol.
- the composition can include a preservative, a surfactant, an emollient, or a combination of these.
- Bakutrol and bisabolol RAC are combined with polysorbate 20 as the preservative.
- these ingredients are combined with other active ingredients, including for example, salicylic acid or benzoyl peroxide (BPO).
- active ingredients e.g., BPO
- BPO benzoyl peroxide
- a composition includes Bakutrol, bisabolol, polysorbate 20, and other ingredients: salicylic acid, olea europaea (olive) fruit extract, perilla ocymoides leaf extract (e.g., shiso extract powder), sodium PCA, hydroxyethylcellulose, disodium EDTA, gluconolactone, lactic acid, sodium benzoate, dextrin, water, glycolic acid, sodium hydroxide, and butylene glycol.
- the composition can include Bakutrol and any one or more of the ingredients, in any combination.
- a method of preparation is for a water-based acne gel composition.
- the preparation solubilizes Bakutrol which allows it to be effectively absorbed by the skin, and allows it to be stable in the gel.
- the gel is effective in reducing inflammatory acne lesions by 50 percent in as few as about 7 days with a 90 percent reduction achieved in about 14 days.
- the gel does not cause collateral damage to the skin, including dry skin, skin irritation, redness, and peeling.
- a method of preparing an aqueous mixture includes: mixing deionized water and hydroxyethylcellulose to obtain a first mixture; applying heat to the first mixture until the first mixture reaches about 75 degrees Celsius; adding disodium
- ethylenediaminetetraacetic acid EDTA
- PCA sodium pyrrolidone carboxylic acid
- the method further includes: mixing deionized water and perilla ocymoides leaf extract to obtain an eighth mixture; mixing the eighth mixture and the seventh mixture to obtain a ninth mixture; mixing deionized water and olea europaea fruit extract to obtain a tenth mixture; mixing the tenth mixture and ninth mixture to obtain an eleventh mixture; allowing the eleventh mixture to cool to from about 40 to 45 degrees Celsius; adding sodium benzoate to the eleventh mixture and mixing to obtain a twelfth mixture; and solubilizing an unsolubilized hydrolyzed psoralea corylifolia extract to obtain a solubilized hydrolyzed psoralea corylifolia extract including mixing the unsolubilized hydrolyzed psoralea corylifolia extract, bisabolol, and polysorbate 20 to obtain a thirteenth mixture, and adding the thirteenth mixture to the twelfth mixture at a temperature of less than about 40 degrees Celsius to obtain a fourteenth mixture
- the method further includes: mixing encapsulated retinol to the fourteenth mixture to obtain a fifteenth mixture; allowing the fifteenth mixture to cool to about 35 degrees Celsius; and obtaining an aqueous mixture that is a combination of the twelfth and thirteenth mixtures and retinol, where the aqueous mixture includes an oil-free, water-based, anti-acne gel.
- the method can further include adding benzoyl peroxide to the polysorbate 20, bisabolol, and hydrolyzed psoralea corylifolia extract of the thirteenth mixture.
- the aqueous mixture can include at least one of a retinoid or an antibiotic.
- the hydrolyzed psoralea corylifolia extract can include bakuchiol.
- the aqueous mixture does not include an alcohol or oil constituent.
- the solubilizing an unsolubilized hydrolyzed psoralea corylifolia at a temperature of less than about 40 degrees Celsius results in a particle size of bakuchiol in the hydrolyzed psoralea corylifolia extract that is of a sufficiently small size to penetrate skin pores into sebaceous follicles where the hydrolyzed psoralea corylifolia extract can exert its antimicrobial and anti-inflammatory properties.
- a mixture includes: hydrolyzed psoralea corylifolia extract; bisabolol, where the hydrolyzed psoralea corylifolia extract and bisabolol are solubulized together; retinol; and a surfactant, where the mixture is aqueous solution without oil and without an alcohol.
- the mixture can further include at least one of benzoyl peroxide, tretinoin, tazarotene, or an antibiotic.
- the antibiotic can be clindamycin or erythromycin.
- a ratio of hydro lyzed psoralea corylifolia extract to bisabolol is about 10:1 or less.
- the retinol can be an encapsulated retinol.
- the retinol can be an unencapsulated retinol; then the hydrolyzed psoralea corylifolia extract, bisabolol, and unencapsulated retinol are solubulized together.
- the surfactant can include cocamidopropyl betaine having a weight- weight percentage greater than 10 percent.
- the surfactant can include decyl glucoside having a weight-weight percentage greater than 20 percent.
- the surfactant can include cocamidopropyl betaine having a weight- weight percentage greater than 10 percent and decyl glucoside having a weight-weight percentage greater than 20 percent.
- the surfactant can include polysorbate 20 having a weight-weight percentage less than 3 percent. Further, the surfactant can include polysorbate 20 having a weight- weight percentage less than 3 percent, and without cocamidopropyl betaine or decyl glucoside, such as in the cleanser formulation.
- Acne is a common skin condition, characterized by areas of skin with seborrhea (scaly red skin), comedones (blackheads and whiteheads), papules (pinheads), pustules (pimples), nodules (large papules) and possibly scarring.
- the available topical agents for the treatment of acne typically include benzoyl peroxide, retinoids, antibiotics, antiseborrheic medications, antiandrogen medications, hormonal treatments, salicylic acid, alpha hydroxy acid, and a combination of these.
- the therapeutic success in acne of these treatments is highly dependent on a regular application of the topical agents over a prolonged period of time.
- disadvantages associated with these commonly used topical agents considerably affect patient compliance and obstruct the treatment. These agents can cause undesirable side effects such as excessive dryness, redness, irritation, and peeling.
- the use of antibiotics has limitations due to development of resistance by bacteria.
- the use of retinoids has also been linked to causing developmental malformations.
- Bakutrol(TM) is an antimicrobial and anti-inflammatory agent that has been shown to help reduce the bacterial activity, inflammation, and scarring seen in acne.
- Bakutrol is a trademark of Unigen, Inc. Any trademarks listed in this patent application are the property of their respective owners.
- Bakutrol is a natural, botanical agent. It contains bakuchiol, a natural phenol isolated from the seeds of Psoralea corylifolia or Psoralea glandulosa, a tree native to China known for its uses in traditional Chinese medicine.
- Bakuchiol has a natural ability to fight inflammation, by controlling leukocytic functions at the site of the inflammation. In clinical studies, Bakutrol reduced both
- Bakuchiol also possesses protective antioxidant characteristics due to its scavenging activity against oxidative damage to lipids and proteins. Additionally, Bakutrol significantly reduces scarring or post-inflammatory hyperpigmentation (PIH), the dark spots left behind long after the acne lesion has healed. Unlike traditional acne treatments, Bakutrol has been clinically proven to reduce PIH. In some studies, bakuchiol has been shown to be more potent at treating acne than benzoyl peroxide.
- a novel technology includes a unique formulation and preparation of a solution in which bakuchiol (Bakutrol) is solubilized, without the use of alcohol.
- Bakutrol When Bakutrol is solubilized, it can be effectively delivered into the sebaceous follicles (pores) with ingredients such as bisabolol where these ingredients, with salicylic acid, can promote rapid clinical results.
- Solubilized Bakutrol can be easily absorbed by the skin. Hence, the skin treatment properties of Bakutrol are significantly enhanced when it is solubilized.
- bakuchiol from hydrolyzed psoralea corylifolia extract
- bakuchiol and the other hydrophobic ingredient are premixed at room temperature in a mixing vessel.
- the hydrophobic molecules of the ingredients can be mixed together without precipitation because hydrophobic molecules form stable
- the mixture containing the solubilized bakuchiol can then be emulsified into a solution to obtain a skincare product. This method yields a stable formula whereby the bakuchiol is completely solubilized.
- bakuchiol can be solubilized to allow for a composition with enhanced acne treatment properties. As discussed above, when bakuchiol is solubilized, it can be effectively absorbed into the skin to treat the skin.
- the product a water-based acne gel
- the product was also seen to work about three times faster than typical prescription and over-the-counter acne products. The results showed that the product does not cause collateral damage to the skin, including dry skin, skin irritation, redness, and peeling.
- bakuchiol is stable in the product, while retaining its acne treatment properties.
- Some accelerated stability studies show that the product is stable for about one month to about 3 months at 25 degrees Celsius, 4 degrees Celsius, and 40 degrees Celsius, with no separation or precipitation. This correlates to about an 8 month to about 24 months shelf life.
- bakuchiol is solubilized using another hydrophobic ingredient, bisabolol.
- Bisabolol is the main active ingredient of the medical plant chamomile (matricaria chamomilla). Bisabolol protects and heals the skin from the effects of daily stress. It is a naturally occurring active ingredient that accelerates the healing process of skin.
- Both bisabolol and bakuchiol have hydrophobic properties and are generally insoluble in water and other aqueous solutions. They are typically formulated into the oil phase of emulsions. However, the bakuchiol (from hydro lyzed psoralea corylifolia extract) will not stay in solution and precipitates out when added to the oil phase of an emulsion. This prevents the hydrolyzed psoralea corylifolia extract from being absorbed by the pores of the skin. [37] Thus, to solubilize bakuchiol, bakuchiol is premixed with bisabolol.
- Bakuchiol and bisabolol can be mixed together without precipitation because hydrophobic molecules form hydrophobic interactions with one another.
- the mixture, containing the solubilized bakuchiol, can then be emulsified into an emulsion. This method yields a stable formula whereby the bakuchiol is completely solubilized.
- a composition includes hydrolyzed psoralea corylifolia, containing bakuchiol as its primary component (or Bakutrol) and bisabolol.
- the composition can include a polysorbate surfactant, which is a stable and relatively nontoxic agent that allows it to be used as a detergent and emulsifier in a number of domestic, scientific, and pharmacological applications. In pharmaceutical applications, it is used to stabilize emulsions and suspensions.
- bakuchiol and bisabolol RAC are combined with polysorbate 20 as the emulsifier.
- a composition includes bakuchiol (or hydrolyzed psoralea corylifoli extract), bisabolol, polysorbate 20, and other ingredients: salicylic acid, olea europaea (olive) fruit extract, perilla ocymoides leaf extract (e.g., shiso extract powder), sodium PCA, hydroxyethylcellulose, disodium EDTA, gluconolactone, lactic acid, sodium benzoate, dextrin, water, glycolic acid, sodium hydroxide, butylene glycol, or any
- the composition can include bakuchiol and any one or more of the ingredients, in any combination.
- Other ingredients can be substituted for or replace any of the one or more of the listed ingredients.
- polysorbate 20 can be replaced by caprylyl glycol, ethylhexylglycerin, or PPG- 2 isoceteth-20 acetate.
- a mixture includes hydrolyzed psoralea corylifolia extract (e.g., bakuchiol), bisabolol, salicylic acid, and a surfactant, in an aqueous solution.
- this mixture can be combined with benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic, or a combination of these.
- antibiotics include clindamycin or erythromycin.
- the mixture can include any combination of antibiotics.
- polysorbate 20 can be used to emulsify these ingredients into a finished formulation.
- a mixture includes bakutrol, bisabolol, polysorbate 20, and at least one of the lipophilic compounds: anti-acne compounds (e.g. benzoyl peroxide, or salicylic acid, or others), retinoids (e.g., retinol, tretinoin, tazarotene, or others), antibiotics (e.g., erythromycin, clindamycin, or others), or any combination of these.
- anti-acne compounds e.g. benzoyl peroxide, or salicylic acid, or others
- retinoids e.g., retinol, tretinoin, tazarotene, or others
- antibiotics e.g., erythromycin, clindamycin, or others
- mixtures can include bakutrol, bisabolol, polysorbate 20 and one of the following: tretinoin, tazarotene, retinol, or benzoyl peroxide.
- tretinoin tazarotene
- retinol retinol
- benzoyl peroxide The relative degrees of efficacies of the above mixtures can be arranged in the following manner (from most efficacious mixture to least efficacious): (1) tretinoin, (2) tazarotene, (3) retinol, and (4) benzoyl peroxide.
- mixtures can have a different arrangement of relative degrees of efficacy.
- another implementation of mixtures can include bakutrol, bisabolol, polysorbate 20 and two of the following: tretinoin, tazarotene, retinol, or benzoyl peroxide.
- a specific implementation can include bakutrol, bisabolol, polysorbate 20, retinol (third most efficacious in another implementation), and benzoyl peroxide (least efficacious in another implementation).
- This mixture can be more efficacious than a mixture including bakutrol, bisabolol, polysorbate 20, tretinoin (most efficacious in another implementation), and tazarotene (second most efficacious in another implementation).
- the relative degrees of efficacies can change because a combination of lipophilic compounds can have a synergistic effect on efficacy.
- a mixture including bakutrol, bisabolol, polysorbate 20, retinol, and benzoyl peroxide can be more efficacious than the combined additive efficacy of (1) a mixture including bakutrol, bisabolol, polysorbate 20, and retinol, and (2) a mixture including bakutrol, bisabolol, polysorbate 20, and benzoyl peroxide.
- one combination of lipophilic compounds can have a stronger synergistic effect on efficacy than a second combination of lipophilic compounds.
- a mixture including bakutrol, bisabolol, polysorbate 20, retinol, and benzoyl peroxide can have a stronger synergistic effect on efficacy and be more efficacious than a mixture including bakutrol, bisabolol, polysorbate 20, tretinoin, and tazarotene, which can have a weaker synergistic effect on efficacy.
- Tetracycline is an antibiotic sometimes used in the treatment of acne vulgaris and is usually administered orally. Tetracycline can be used in topical form to treat acne vulgaris, but generally has poor absorption into the skin. So, other antibiotics are typically better suited for topical formulations than tetracycline.
- hydrophobic ingredients such as benzoyl peroxide, tretinoin, retinol, tazarotene and other hydrophobic ingredients are generally insoluble in water and other aqueous solutions.
- hydrophobic ingredients such as bakuchiol or bisabolol, or both.
- bakuchiol which has a similar hydrophobicity value (octanol-water partition coefficient) to that of tretinoin, retinol, and tazarotene, and a greater hydrophobicity value than that of benzoyl peroxide, can be used to solubilize these ingredients.
- bisabolol which is similar in structure and hydrophobicity to ingredients such as retinoids and retinol, can also be used to solubilize retinoids such as tretinoin and retinol.
- polar i.e., hydrophilic
- nonpolar i.e., hydrophobic
- a mixture of bakuchiol, bakutrol, and polysorbate 20, along with other ingredients such as salicylic acid, can be used to solubilize other similar hydrophobic anti-acne ingredients such as tretinoin, retinol, tazarotene and benzoyl peroxide without the use of alcohol or other solvents that may irritate skin.
- This method yields a stable formula in which the hydrophobic ingredients are solubilized.
- a specific implementation of the mixture described in this patent is an aqueous solution.
- An aqueous solution is used for an acne formulation because it is gentler, and irritates the skin less than a nonaqueous solution.
- Nonaqueous solution can irritate the skin and may cause inflammation, which can make the acne condition to worsen (e.g., cause acne breakouts, make the skin more sensitive, or enlarge the affected area).
- a mixture as described in this patent can include a nonaqueous solvent.
- These nonaqueous solvents can be added in trace or as a relatively small percentage (or greater) of the total mixture.
- Such nonaqueous solvents can help in the dissolution of some of the components of the mixture, improve stability of the mixture, used to adjust the pH balance or polarity of the solution, or other.
- a mixture with nonaqueous solvents can be used for specific acne conditions or acne in particular areas of the body that do not respond or adhere as well to aqueous solvents (e.g., near sweat glands where the mixture would get washed or flushed away quickly).
- a mixture can include one or more solvents, other than water, including a polar solvent or nonpolar solvent, or a combination of these.
- solvents include alcohol, isododecane, octyldodecanol, heptane, pentane, or benzyl benzoate.
- the mixture can include any combination of solvents with or without water.
- the hydrolyzed psoralea corylifolia extract (e.g., bakuchiol) of the mixture can be substituted with benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic, or a combination of these.
- the bisabolol of the mixture can be substituted with benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic, or a combination of these.
- a composition includes bakuchiol and bisabolol in an aqueous solution.
- the composition can be combined with other ingredients such as one or more anti-acne compounds (e.g., salicylic acid, benzoyl peroxide, and many others), one or more retinoids (e.g., retinol, tretinoin, tazarotene, and many others), one or more antibiotics (e.g., erythromycin, clindamycin, and many others), one or more surfactants, or one or more emollients, or any combination of these.
- anti-acne compounds e.g., salicylic acid, benzoyl peroxide, and many others
- retinoids e.g., retinol, tretinoin, tazarotene, and many others
- antibiotics e.g., erythromycin, clindamycin, and many others
- surfactants e.g.
- Salicylic acid is a keratolytic agent with anti-inflammatory properties.
- Benzoyl peroxide is a keratolytic agent with antibacterial properties. Because salicylic acid and benzoyl peroxide treat acne in different ways (anti-inflammation versus antibacterial), salicylic acid and benzoyl peroxide can be combined together to treat acne in multiple ways and result in a more effective anti-acne product. Because salicylic acid and benzoyl peroxide are both keratolytic agents, salicylic acid and benzoyl peroxide can also substitute for each other in a mixture.
- an over-the-counter product can have benzoyl peroxide, as the single active ingredient, in concentrations of 2.5 percent to 10 percent.
- a product can have salicylic acid, as the single active ingredient, in concentrations of
- a product can have sulfur, as the single active ingredient, in concentrations of 3 percent to 10 percent.
- an over-the-counter anti-acne product can have a combination of resorcinol in a concentration of 2 percent and sulfur in concentrations of 3 percent to 8 percent.
- a product can have a combination of resorcinol monoacetate in a concentration of 3 percent and sulfur in concentrations of 3 percent to 8 percent.
- the mixture includes salicylic acid or the like, without benzoyl peroxide or the like.
- the composition includes bakuchiol and bisabolol and at least one of benzoyl peroxide, salicylic acid, tretinoin, retinol, tazarotene, or an antibiotic.
- any one of the ingredients can be omitted or replaced with another ingredient such as an anti-acne compound, an antioxidant, a sunscreen agent, a vitamin, retinol, a retinoid, an anti-inflammatory, an analgesic, or an antibiotic, or any combination of these.
- the bisabolol of the composition of bakuchiol and bisabolol is substituted with at least one of benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic, or a combination of these.
- the composition includes bakuchiol, salicylic acid, and at least one of benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic.
- the bakuchiol of the composition of bakuchiol and bisabolol is substituted with at least one of benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic, or a combination of these.
- benzoyl peroxide tretinoin
- retinol retinol
- tazarotene or an antibiotic, or a combination of these.
- the composition can include bisabolol, salicylic acid, and at least one of benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic.
- composition in these implementations is not limited to the specific ingredients presented.
- a composition may have additional compounds (not necessarily described in this application), different compounds which replace some of the compounds presented, fewer of the compounds presented, or any combination of these.
- Bakutrol and bisabolol can be combined with other active ingredients (not presented above) such as benzoyl peroxide, retinoids (e.g., retinol and tretinoin), and antibiotics (e.g., erythromycin and clindamycin), and the remainder is an emollient, water and other solvents.
- bakuchiol e.g., other solvents such as caprylyl glycol, ethylhexylglycerin, PPG-2 isoceteth-20 acetate, and others.
- Table A provides the range of amount (percentage by weight) of each ingredient that can be used, while still maintaining its efficacy as an acne treatment agent.
- ingredient column a trade name (in parentheses) for a product having the ingredients listed is also given. It should be understood that the invention is not limited to the specific percentages presented. A formulation of the invention may have additional compounds (not necessarily described in this application), different compounds which replace some of the compounds presented, fewer of the compounds presented, or any combination of these.
- the compounds in other implementations of the invention may not be exactly the same as the compounds presented and may be modified or altered as appropriate for a particular application or based on the data or situation.
- the percentages can also be specified by volume.
- a composition for an acne solution includes 0.01 percent to about 1 percent by weight of bakuchiol, and about 0.01 percent to about 1 percent by weight of bisabolol RAC.
- the ratio of bakuchiol to bisabolol RAC is about 12: 1, 12.8: 1 11 : 1, 11.5: 1, 10: 1, 10.1 : 1, 10.2:1 10.5: 1, 10.8: 1 9: 1, 9.5: 1, 9.7: 1, 9.8:1, 9.9: 1, 8: 1, 8.25: 1, or 8.5: 1.
- this ratio can vary.
- the composition can include a greater amount of bisabolol than of bakuchiol. In these implementations, the ratio can be about 1 : 1, 1 :2, 1 :4, 1 :6, 1 :8, or 1 : 10.
- the ratios of bisabolol to bakuchiol can vary in different formulas based on the solubility of bakuchiol in each of the formulas.
- one implementation of the formula can include bisabolol, bakuchiol, polysorbate 20, and salicylic acid.
- Another implementation of the formula can include bisabolol, bakuchiol, polysorbate 20, and benzoyl peroxide.
- the solubility of bakuchiol can be less in the formula with salicylic acid compared to the formula with benzoyl peroxide because bakuchiol is less able to solubilize with salicylic acid.
- varying concentrations of ingredients (active or inactive ingredients) in formulas can change the solubility of bakuchiol in the formulas, thereby changing the ratios of bisabolol to bakuchiol.
- one implementation of the formula can include bisabolol, bakuchiol, polysorbate 20, and 0.5 percent salicylic acid.
- Another implementation of the formula can include bisabolol, bakuchiol, polysorbate 20, and 1 percent salicylic acid.
- Bakuchiol' s solubility in the formula with 0.5 percent salicylic acid can be different from its solubility in the formula with 1 percent salicylic acid. And the different solubility can affect the ratio of bisabolol to bakuchiol.
- the ratios of bisabolol to bakuchiol can vary from a gel formula to a cleanser formula.
- the reason for the different ratios can be due to different active or inactive ingredients that are present in a gel formula and not present in a cleanser formula, or due to ingredients that are present in a cleanser formula and not present in a gel formula.
- a gel formula can contain the same ingredients as the cleanser formula, but in different concentrations. The different concentrations can result in different ratios of bisabolol to bakuchiol in a gel formula compared to a cleanser formula.
- a composition includes about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.05, 0.06, 0.07, 0.075, 0.09, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 percent by weight of bakuchiol. Additionally, the composition can include about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.05, 0.06, 0.07, 0.075, 0.09, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 percent of bisabolol RAC. Bakuchiol and bisabolol can be present in any combination of percentages, either individually or in combination.
- Salicylic acid can be included in the composition in a range of about 0.10 percent to about 5.0 percent by weight. Salicylic acid is typically used to treat skin conditions including acne. The amount salicylic acid can vary in this range as appropriate for a particular application or based on the data or situation. In a specific implementation, the ratio of salicylic acid to bakuchiol is about 12:1, 12.8: 1 11 : 1, 11.5: 1, 10: 1, 10.1 : 1, 10.2: 1 10.5: 1, 10.8:1 9: 1, 9.5: 1, 9.7: 1, 9.8: 1, 9.9: 1, 8: 1, 8.25: 1, or 8.5: 1. In other implementations, this ratio can vary. The composition can include a greater amount of bakuchiol than of salicylic acid.
- the ratio can be about 1 : 1, 1 :2, 1 :3, 1 :4, 1 :5, 1 :6, 1 :7, 1 :8, 1 :9 or 1 : 10.
- the composition includes about 0.5, 0.7, 0.75, 0.8, 0.85, 0.9, 0.95, 1.0, 1.05, 1.1, 1.15, 1.2, 1.25, 1.3, 1.35, 1.4, 1.5, 2.0, 2.5, 3.0, 4.0, or 5.0 percent by weight of salicylic acid.
- salicylic acid is present in an amount from about 0.5 percent to about 2 percent by weight (or equivalent amount by volume).
- At least one of the ingredients presented in table A can be combined in any combination with benzoyl peroxide, tretinoin, retinol, tazarotene, or an antibiotic, or a combination of these.
- antibiotics include clindamycin or erythromycin.
- Benzoyl peroxide, tretinoin, retinol, tazarotene, or a hydrophobic antibiotic can be solubilized and developed into a formula similar to one listed in table A.
- a method to solubilize the above ingredients can include the same steps 1-9 in table B.
- step 10 (which is similar to step 10 of table B) of this implementation, benzoyl peroxide, tretinoin, retinol, tazarotene or a hydrophobic antibiotic can be premixed individually (not together in the same formula) with polysorbate 20 (item #16), bakuchiol (item #17), and bisabolol (item #18A) and mixed until uniform. Then the premix can be added to the first processing tank and mixed until completely uniform.
- a method to solubilize the above ingredients can include the same steps 1-9 in table B.
- the two or more ingredients to be solubilized can be premixed individually with polysorbate 20 (item #16), bakuchiol (item #17), and bisabolol (item #18A) and mixed until uniform.
- premixing the ingredients individually with items #16, #17, and #18A is to premix the first ingredient with item #16, #17, and #18A and to premix the second ingredient with item #16, #17, and #18A, and so on for a third or fourth ingredient to be solubilized. Then the premixes can be added to the first processing tank and mixed until completely uniform.
- a method to solubilize the above ingredients can include the same steps 1-9 depicted in table B.
- the ingredients to be solubilized can be combined together, then premixed with polysorbate 20 (item #16), bakuchiol (item #17), and bisabolol (item #18A), and mixed until uniform. Then the premix can be added to the first processing tank and mixed until completely uniform.
- the composition can include about 2.5 percent to about 10 percent by weight (or equivalent amount by volume) of benzoyl peroxide.
- the composition includes about 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, or 10 percent by weight.
- the composition includes 10 percent by weight or greater of benzoyl peroxide, for example, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11, 12, 13, 14, or 15 percent or greater.
- the composition includes less than 2.5 percent by weight of benzoyl peroxide.
- the composition includes 0.1, 0.5, 1, 1.5, 2.0, 2.1, 2.2, 2.3, or 2.4 percent or greater.
- the composition can include about 0.025 percent to about 0.1 percent by weight (or equivalent amount by volume) of tretinoin.
- the composition includes about 0.025, 0.05, 0.075, or 0.1 percent by weight.
- the composition includes 0.1 percent by weight or greater of tretinoin, for example, 0.125, 0.15, 0.175, or 0.2 percent or greater. In other
- the composition includes less than 0.025 percent by weight of tretinoin.
- the composition includes about 0.02, 0.015, 0.01, 0.005, or 0.001 percent or less.
- the composition can include about 0.1 percent by weight (or equivalent amount by volume) of tazarotene.
- the composition includes 0.1 percent by weight or greater of tazarotene, for example, 0.125, 0.15, 0.175, or 0.2 percent or greater.
- the composition includes less than 0.1 percent by weight of tazarotene.
- the composition includes 0.09, 0.008, 0.07, 0.06, or 0.05 percent or less.
- the composition can include about 1 percent to about 1.2 percent by weight (or equivalent amount by volume) of clindamycin.
- the composition includes about 1, 1.05, 1.1, 1.15, or 1.2 percent by weight.
- the composition includes 1.2 percent by weight or greater of clindamycin, for example, 1.2, 1.25, 1.3, 1.35, 1.4, 1.45, or 1.5 percent or greater.
- the composition includes less than 1 percent by weight of clindamycin.
- the composition includes about 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, or 0.1 percent or less.
- the composition can include about 2 percent to about 3 percent by weight (or equivalent amount by volume) of erythromycin.
- the composition includes about 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, or 3 percent by weight.
- the composition includes greater than about 3 percent of erythromycin, for example, 3, 3.1, 3.2, 3.3, 3.4, or 3.5 percent or greater.
- the composition includes less than 2 percent by weight of erythromycin.
- the composition includes about 1.9, 1.8, 1.7, 1.6, 1.5, 1.4, 1.3, 1.2, 1.1, 1 , or 0.5 percent or less.
- the composition can include retinol.
- Retinol is a cosmetic ingredient and can be used in a wide range of concentrations.
- the amount of retinol in the composition can be from about 0.01 percent to about 20 percent.
- the composition includes about 0.01, 0.1, 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 10, 15, or 20 percent by weight.
- the composition includes 20 percent by weight or greater of retinol, for example, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 percent or greater.
- the composition includes less than 0.01 percent by weight of retinol.
- the composition includes about 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002, or 0.001 percent or less.
- the composition includes alpha hydroxy acid (AHA).
- alpha hydroxy acid can include one or more of glycolic acid, lactic acid, malic acid, citric acid, tartaric acid, or suitable mixtures of two or more thereof.
- the composition includes about 10 percent to about 20 percent of glycolic acid, and 0.10 percent to about 5 percent of lactic acid.
- glycolic acid is present in about 10.5, 11.5, 12.5, 13, 13.5, 13.8, 14.0, 14.1, 14.3, 14.5, 14.8, 15.0, 15.3, 15.8, 16.0, 16.5, or 17.0 percent
- lactic acid is present in about 0.15, 0.3, 0.5, 0.7, 0.75, 0.8, 0.9, 0.95, 1.0, 1.1, 1.3, 1.4, 1.6, 1.7, 2.0, 2.4, 2.9, 3.0, 3.5, or 4.0 percent. The amount of this
- combination of alpha hydroxy acids can be included individually or in combination.
- the composition can include an extract derived from Perilla Ocymoides in an amount from about 0.01 to about 1.0 percent.
- the amount of extract is about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.05, 0.06, 0.07, 0.075, 0.09, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 percent by weight.
- the extract is an extract power from shiso.
- the composition can also include an extract derived from the Olea Europaea fruit, in an amount from about 0.01 to about 1.0 percent.
- the amount of extract is about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.05, 0.06, 0.07, 0.075, 0.09, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 percent by weight.
- the fruit is commonly called the olive.
- the composition can include hydroxy ethylcellulose in an amount from about 0.1 to about 5.0 percent.
- the amount can be about 0.15, 0.3, 0.5, 0.7, 0.75, 0.8, 0.9, 0.95, 1.0, 1.1, 1.3, 1.4, 1.6, 1.7, 2.0, 2.4, 2.9, 3.0, 3.5, 4.0, 4.5, or 5.0 percent by weight.
- Disodium EDTA can be included in an amount from about 0.01 to about 1 percent.
- the amount of disodium EDTA is about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.05, 0.06, 0.07, 0.075, 0.09, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 percent by weight.
- Sodium PCA can be included in an amount from about 0.1 to about 5.0 percent.
- the amount can be about 0.15, 0.3, 0.5, 0.7, 0.75, 0.8, 0.9, 0.95, 1.0, 1.1, 1.3, 1.4, 1.6, 1.7, 2.0, 2.4, 2.9, 3.0, 3.5, 4.0, 4.5, or 5.0 percent by weight.
- the composition can include butylene glycol in an amount from about 0.1 to about 5.0 percent.
- the amount can be about 0.15, 0.3, 0.5, 0.7, 0.75, 0.8, 0.9, 0.95, 1.0, 1.1, 1.3, 1.4, 1.6, 1.7, 1.9, 1.95, 2.0, 2.05, 2.1, 2.2, 2.3, 2.4, 2.9, 3.0, 3.5, 4.0, 4.5, or 5.0 percent by weight.
- the composition can include sodium hydroxide in an amount from about 0.1 to about 5.0 percent.
- the amount can be about 0.15, 0.3, 0.5, 0.7, 0.75, 0.8, 0.9, 0.95, 1.0, 1.1, 1.3, 1.4, 1.6, 1.7, 1.9, 1.95, 2.0, 2.05, 2.1, 2.2, 2.3, 2.4, 2.9, 3.0, 3.5, 4.0, 4.5, or 5.0 percent by weight.
- the composition can include sodium benzoate in an amount from about 0.1 to about 5.0 percent.
- the amount can be about 0.15, 0.3, 0.5, 0.7, 0.75, 0.8, 0.9, 0.95, 1.0, 1.1, 1.3, 1.4, 1.6, 1.7, 1.9, 1.95, 2.0, 2.05, 2.1, 2.2, 2.3, 2.4, 2.9, 3.0, 3.5, 4.0, 4.5, or 5.0 percent by weight.
- the composition includes sodium benzoate with gluconolactone.
- the composition can include other ingredients including preservatives, thickeners, humectants, stabilizers, buffers, emollients, emulsifying agents, and water.
- the composition includes about 1 percent to about 5 percent by weight of polysorbate 20. For example, an amount of about 1.0, 1.1, 1.3, 1.4, 1.6, 1.7, 1.9, 1.95, 2.0, 2.05, 2.1, 2.2, 2.3, 2.4, 2.9, 3.0, 3.5, 4.0, 4.5, or 5.0 percent by weight is included.
- polysorbate 20 can be substituted with 0.01 percent to about 1 percent of caprylyl glycol.
- an amount of about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.05, 0.06, 0.07, 0.075, 0.09, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 percent by weight is included.
- caprylyl glycol can be substituted with 0.01 percent to about 1 percent of ethylhexylglycerin.
- an amount of about 0.01, 0.015, 0.02, 0.025, 0.03, 0.035, 0.05, 0.06, 0.07, 0.075, 0.09, 0.1, 0.2, 0.25, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, or 1.0 percent by weight is included.
- ethylhexylglycerin can be substituted with 0.1 percent to about 3 percent of PPG-2 isoceteth-20 acetate.
- an amount of about 0.15, 0.3, 0.5, 0.7, 0.75, 0.8, 0.9, 0.95, 1.0, 1.1, 1.3, 1.4, 1.6, 1.7, 1.9, 1.95, 2.0, 2.05, 2.1, 2.2, 2.3, 2.4, 2.9, or 3.0 percent by weight is included.
- other ingredients' weight by percentage can be adjusted accordingly.
- an amount of deionized water can be increased or decreased accordingly.
- the amount of water in the final composition can be from about 45 to about 99 percent.
- deionized water is included in an amount of about 70, 70.5, 70.3, 70.9, 72.5, 72.9, 73.0, 73.1, 73.3, 73.4, 73.5, 73.6, 73.7, 73.9, 80.1, 80.15, 80.2, or 81.0 percent by weight.
- the composition can be formulated as a water-based, topical gel. In a specific implementation, the gel is a semiviscous gel solution.
- the solution can have a specific gravity from about 1.06 to 1.10, about 17.5 percent to about 21.5 percent of solids, a viscosity of about 4000 to about 8000 centipoise (cps), and a pH of about 3.5 to about 4.5.
- Gels can be a solid three-dimensional network that spans the volume of a liquid medium and ensnares it through surface tension effects. This internal network structure may result from physical bonds (physical gels) or chemical bonds (chemical gels), as well as crystallites or other junctions that remain intact within the extending fluid.
- a gel vehicle with an aqueous nature can ensure that sebaceous follicles or pores do not get clogged with oils. Therefore, a water-based gel devoid of oils can be beneficial to skin.
- the composition can also be formulated as a serum.
- a serum can be oil and water- based.
- a serum can be more difficult to apply onto the skin.
- a serum formulation can be desirable because a serum (compared to lotion, cream, and gel) is characterized by its rapid absorption, ability to penetrate into the deeper layers of the skin, nongreasy finish, and a formulation with a very high concentration of active substances (e.g., lipophilic compounds, anti-acne compounds, or retinoids, or antibiotics).
- active substances e.g., lipophilic compounds, anti-acne compounds, or retinoids, or antibiotics.
- the composition can also be formulated as a lotion, which can be an oil-in-water emulsion or water-in-oil emulsion.
- Lotions can include fillers and emulsifiers to create a creamy lotion, and can introduce pore-clogging oils onto the skin.
- the oils, fillers, and emulsifiers can irritate and worsen acne.
- such oils may not clog pores, and can instead improve acne by moisturizing and soothing dry skin.
- the composition can be included in a cleanser, cream, lotion, serum, essence, balm, sunscreen, gel, or an emulsion (e.g., an oil-in-water emulsion or a water-in-oil emulsion).
- the composition can be included in a group of products (e.g., day cream, night cream, cleanser, toner, and acne gel), prescribed for use together, in order to maximize the acne treatment properties of the composition.
- the composition can be alcohol-free or substantially alcohol-free.
- Formulations can include more or less humectants, oils, botanicals, or other ingredients where the composition is adjusted for different skin types (e.g., dry, oily, acne prone, combination, dull, sensitive, or aging skin).
- a method of preparation includes a water-based acne gel composition.
- the preparation solubilizes bakuchiol (e.g. Bakutrol) and allows it to be stable in the gel.
- bakuchiol e.g. Bakutrol
- a problem is bakuchiol (e.g., 60 percent of hydrolyzed psoralea corylifolia extract, such as found in Envy Medical's ClarityMD Cleanser and Gel) and bisabolol are very insoluble in water. Both bisabolol and bakuchiol are typically formulated into the oil phase of emulsions, per the ingredient manufacturers. However, the hydrolyzed psoralea corylifolia extract (60 percent bakuchiol) will not stay in solution and precipitates out when added to the oil phase of an emulsion. This prevents the hydrolyzed psoralea corylifolia extract from being absorbed by the pores of the skin. A more stable formula can be achieved if alcohol is added to the formula, but the alcohol is undesirable as it will irritate inflammatory acne lesions.
- an acne cleanser formula can include less than 50 percent water.
- an acne gel formula can include less than 60 percent water.
- An acne cleanser formula including less than 50 percent water or an acne gel formula including less than 60 percent water can result in a more anhydrous formula composed mostly of oil or silicone, which would not be ideal for application onto acneic skin. However, a more anhydrous formula with oils or silicone can be moisturizing and soothing for people with dry skin and acne.
- an acne cleanser formula can include more than 50 percent water. And in an implementation, an acne gel formula can include more than 60 percent water. In a more specific implementation, an acne cleanser can include 55-65 percent water. In another specific implementation, an acne gel formula can include more than 70-75 percent water. Since anti-acne ingredients are typically hydrophobic, the concentration of water may not impact effectiveness of the cleanser or gel in addressing acne.
- a method is used to obtain a formulation of an acne cleanser.
- the method includes premixing hydrolyzed psoralea corylifolia extract with alpha-bisabolol, Eurol BT, olea europaea (olive) fruit extract, phenoxyethanol, caprylyl glycol, hexylene glycol, ethylhexylglycerine, cocamidopropyl betaine, and sodium chloride, and then adding this mixture to the cleanser formula.
- the method yields a stable formula whereby the hydrolyzed psoralea corylifolia extract is completely solubilized.
- a method is used to obtain a formulation of an acne gel.
- the method includes premixing hydrolyzed psoralea corylifolia extract with polysorbate 20 and bisabolol and then adding this mixture to the gel formula. The method yields a stable formula whereby the hydrolyzed psoralea corylifolia extract is completely solubilized.
- the procedure listed below in table B provides a specific example of a preparation of a water-based acne gel including solubilized bakuchiol.
- the item numbers presented in table B are the item numbers as presented in table A above.
- the amount of each item is according to the ranges presented in table A, and in the specific implementations provided above. It should be understood that the invention is not limited to the specific percentages presented.
- a formulation of the invention may have additional compounds (not necessarily described in this application), different compounds which replace some of the compounds presented, fewer of the compounds presented, or any combination of these.
- the compounds in other implementations of the invention may not be exactly the same as the compounds presented and may be modified or altered as appropriate for a particular application or based on the data or situation. For example, the percentages can also be specified by volume.
- mixing time until uniformity of concentration in mixtures is achieved can vary from batch to batch.
- Mixing time can depend on batch size, batch temperature, type of mixing used by the manufacturing kettle, size of the manufacturing kettle, and model of the manufacturing kettle used.
- a manufacturing kettle (or a process kettle) can have different shapes of propellers for mixing.
- the propeller shapes can affect how fast uniformity can be achieved.
- a manufacturing kettle can also have different speed settings for the propellers. For example, a higher speed would help a mixture achieve uniformity faster.
- a lower propeller speed can be from 30-60 revolutions per minute (rpm).
- a higher propeller speed can be from 900-3600 revolutions per minute. Mixing at higher propeller speed would shorten the amount of time for a mixture to achieve uniformity.
- the size of manufacturing kettle can also affect the length of mixing time for a mixture to achieve uniformity.
- a larger sized manufacturing kettle can hold a larger batch of product or mixture. And as discussed above, a larger batch can achieve uniformity slower than a smaller batch.
- the model of manufacturing kettle used can also affect the length of time for a mixture to achieve uniformity.
- One model of manufacturing kettle can have a round shape.
- Another model of manufacturing kettle can have a longer oval shape.
- the different shapes can affect how different layers of fluid flows within the mixture interact with each other (e.g., laminar flow or turbulent flow), which could affect the mixture's speed in achieving uniformity of concentration.
- cooling rates of mixtures can also vary from batch to batch because they depend on the size of the production batch, the manufacturing kettle used, and other equipment factors. A larger batch can require a longer time to cool down. Manufacturing kettles can have different cooling methods built in, such as transferring heat of mixture into cooling water flows. Cooling rates can depend on the manufacturing kettle's capability in cooling a mixture.
- the batch can be mixed inside equipment made of material that is insulating or conductive. Cooling rate can be faster for equipment made of conductive material. And cooling rate can be slower for equipment made of insulating material.
- temperatures are maintained, as directed, for each manufacturing step in approximately real time.
- the temperatures can be maintained using a steam jacket built into the manufacturing kettle.
- the formula is constantly mixed throughout the entire manufacturing process until the production batch meets the formula specifications and is deemed completed.
- the formula may not be constantly mixed.
- the procedure can be paused at a certain step, so that mixing is paused and the batch is be put away to be continued on another day.
- a mix of item #9 and item #10 is a sixth mixture. Slowly add the sixth mixture to the first processing tank. Mix for a sufficient time until uniform, thereby obtaining a seventh mixture. After the seventh mixture is uniform, cool to 45-50 degrees Celsius while concurrently mixing.
- G 7 Add item #15 to the first processing tank. Mix for a sufficient time until uniform while maintaining a temperature of 40-45 degrees Celsius, thereby obtaining a twelfth mixture.
- the fourteenth mixture is an aqueous mixture that is a combination of the twelfth and thirteenth mixtures.
- the fourteenth mixture is a water-based mixture that is a combination of the twelfth and thirteenth mixtures, and the fourteenth mixture does not include an oil constituent.
- the fourteenth mixture is a water-based mixture that is a combination of the twelfth and thirteenth mixtures, and the fourteenth mixture does not include an alcohol constituent.
- oil and alcohol are avoided because they can be skin irritants, which in an acne formulation can make an acne condition worse instead of better.
- the thirteenth mixture is added to the twelfth mixture (which is inside the first processing tank) at a temperature of less than 40 degrees Celsius to obtain a fourteenth mixture.
- the fourteenth mixture includes the solubilized hydrolyzed psoralea corylifolia extract.
- hydrolyzed psoralea corylifolia extract, bisabolol, and polysorbate 20 are solubilized at less than about 40 degrees, which is a lower temperature such as 75 degrees. Solubilizing at a lower temperature provides benefits. Using a lower temperature allows the particle size of bakuchiol in the hydrolyzed psoralea corylifolia extract to be smaller sized.
- the lower temperature allows the particle size of bakuchiol in the hydrolyzed psoralea corylifolia extract to be of sufficiently small size to penetrate skin pores into sebaceous follicles where the hydrolyzed psoralea corylifolia extract can exert its antimicrobial and anti-inflammatory properties.
- step 9 item #19 is added to the fourteenth mixture (which is inside the first processing tank) at a temperature of less than 40 degrees Celsius to obtain a fifteenth mixture.
- the fifteenth mixture includes the solubilized hydrolyzed psoralea corylifolia extract, bisabolol, and encapsulated retinol.
- the combination of retinol and bakuchiol has an improved or synergistic effect on the efficacy in treatment of acne (compared to retinol by itself or bakuchiol by itself).
- the combination is as effective as tretinoin, which is available by prescription.
- retinol does not need to be solubilized with bakuchiol because encapsulated retinol is added to the mixture.
- the capsule of the encapsulated retinol can provide a shield a shield between retinol and bakuchiol and can decrease effects of (unencapsulated) retinol on the ability of bisabolol to solubilize bakuchiol.
- retinol With less interaction between retinol and bakuchiol, retinol does not need to be solubilized with bakuchiol.
- retinol can be added to separately to the mixture, after bakuchiol has been solubilized with bisabolol.
- encapsulated retinol instead of using an encapsulated retinol and unencapsulated retinol can be used to obtain an effective mixture including bakuchiol, bisabolol, and retinol.
- unencapsulated retinol When using unencapsulated retinol, the unencapsulated retinol is solubilized with along with the bakuchiol and bisabolol (step 8 above).
- step 10 item 16 (polysorbate 20) can be substituted with an amount of caprylyl glycol (item #18B), while the other steps and ingredients are the same as presented in table B.
- caprylyl glycol can be substituted with an amount of ethylhexylglycerin (item #18C).
- ethylhexylglycerin can be substituted with an amount of PPG-2 isoceteth-20 acetate (item #18D).
- other ingredients' weight by percentage can be adjusted accordingly. For example, in a
- composition using 1.0 percent PPG-2 isoceteth-20 acetate an amount of deionized water can be decreased or increased accordingly.
- Table C below provides another implementation for an acne cleanser formulation. The of amounts (percentage by weight) of each ingredient are listed, while still maintaining its efficacy as an acne treatment agent (cleanser formulation), similar to table A.
- Aloe barbadensis leaf juice is used as a skin conditioner or moisturizer.
- Aloe barbadensis can be substituted with other forms of aloe, such as Aloe bamadensis leaf juice powder or extract.
- Aloe barbadensis can be substituted with a similar performing skin conditioner using a one to one ratio.
- Aloe barbadensis can be substituted with other skin conditioners using a ratio (Aloe barbadensis to substitute) of 0.01 :1, 0.1 : 1, 0.5:1, 1 : 1, 2: 1, 3: 1, 5: 1, 10: 1, or more.
- the mixture does not contain a skin conditioner.
- Aloe barbadensis can be immaterial to the performance of the formula.
- Xanthan gum can be a gel forming (or viscosity controlling) agent.
- Xanthan gum can be substituted with a similar performing gel forming agent (e.g., Carbopol® 941 and others) using a ratio (Xanthan gum to substitute) of 0.01:1, 0.1:1, 0.5:1, 1:1, 2:1, 3:1 ,5:1, 10:1, or more.
- the mixture does not contain a viscosity controlling agent.
- Decyl glucoside can be used as a surfactant, or a skin cleansing agent, or a
- Decyl glucoside can be substituted with a surfactant (e.g., polysorbate 20 or other surfactants previously mentioned) or with a skin cleansing agent, or with a combination of both surfactant and skin cleansing agent, using a ratio (decyl glucoside to surfactant substitute or decyl glucoside to skin cleansing agent substitute) of 0.01:1, 0.1:1, 0.5:1, 1:1,2:1,3:1 ,5:1, 10:1, or more.
- a surfactant e.g., polysorbate 20 or other surfactants previously mentioned
- More than one type of surfactant can be used.
- decyl glucoside and cocamidopropyl betaine can be combined in a single formula.
- decyl glucoside and cocamidopropyl betaine can be combined in ratios (decyl glucoside to cocamidopropyl betaine) of 1:1, 1.55:1, 1.87:1, 1.94:1, 1.95:1, 2.01:1, 2.05:1, 2.07:1, 2.08:1, 2.09:12.11:1,3.09:1,4.0:1, 1:4, 1:3, 1:2.5, 1:2, 1:1.5, 1:1.05, and more.
- sapindus mukurossi peel extract can be used as a skin conditioning agent, or an anti-irritant, or a combination of both.
- Sapindus mukurossi peel extract can be substituted with a skin conditioning agent or with an anti-irritant, or with a combination of both (e.g., dipotassium glycyrrhizate and others), using a ratio (sapindus mukurossie peel extract to skin conditioning agent substitute or sapindus mukurossie peel extract to anti-irritant substitute) of 0.01:1, 0.1:1, 0.5:1, 1:1,2:1,3:1 ,5:1, 10:1, or more.
- more than one type of skin conditioning agent or anti- irritant can be used.
- sapindus mukurossi peel extract and dipotassium glycyrrhizate can be combined in a single formula.
- sapindus mukurossi peel extract and dipotassium glycyrrhizate can be combined in ratios (sapindus mukurossi peel extract to dipotassium glycyrrhizate) of 1:1, 1.5:1,2:1,3:1,5:1, 10:1, 1:1.5, 1:2, 1:3, 1:5, 1:10, and more.
- table D provides another specific example of preparing a mixture for an acne cleanser including solubilized bakuchiol, similar to table B.
- the item numbers presented in table D are the item numbers as presented in table C above.
- the amount of each item is according to the ranges presented in table C. It should be understood that the invention is not limited to the specific percentages presented in table C.
- F 6 In a fifth processing vessel or tank, add items #10 to #13 at room temperature. Mix mixture inside fifth processing vessel or tank for a sufficient time until uniform. Add mixture inside fifth processing tank to the first processing tank. Mix mixture inside first processing tank until uniform while maintaining a temperature of 50-55 degrees Celsius.
- G 7 In a sixth processing vessel or tank, add items #14 to #18 at room temperature. Mix mixture inside sixth processing vessel or tank for a sufficient time until uniform. Add the mixture inside the sixth processing vessel or tank to the first processing tank. Mix mixture inside first processing tank for a sufficient time until uniform at a temperature of 50-55 degrees Celsius. Then cool mixture inside the first processing tank to 30-35 degrees Celsius.
- the al )ove cleanser formulation can also include retinol, as the gel, lotion, or similar formulation in tables A and B.
- An encapsulated retinol can be mixed with the above mixture after step 7.
- the unencapsulated retinol can be solubilized along with the bakuchiol and bisabolol in step 6.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461982229P | 2014-04-21 | 2014-04-21 | |
PCT/US2015/026958 WO2015164433A1 (en) | 2014-04-21 | 2015-04-21 | Acne solution |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3134078A1 true EP3134078A1 (en) | 2017-03-01 |
EP3134078A4 EP3134078A4 (en) | 2017-12-06 |
Family
ID=54333112
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP15782917.7A Pending EP3134078A4 (en) | 2014-04-21 | 2015-04-21 | Acne solution |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3134078A4 (en) |
BR (1) | BR112016024528B1 (en) |
CA (1) | CA2946124A1 (en) |
WO (1) | WO2015164433A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9949915B2 (en) | 2016-06-10 | 2018-04-24 | Clarity Cosmetics Inc. | Non-comedogenic and non-acnegenic hair and scalp care formulations and method for use |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0424891D0 (en) * | 2004-11-11 | 2004-12-15 | Boots Co Plc | Topical compositions |
US20090137534A1 (en) * | 2007-11-26 | 2009-05-28 | Chaudhuri Ratan K | Skin treatment compositions and methods |
US20100040696A1 (en) * | 2008-08-12 | 2010-02-18 | Ilse Sente | Composite Particles Having An Antioxidant-Based Protective System, And Topical Compositions Comprising The Same |
WO2012106551A1 (en) * | 2011-02-02 | 2012-08-09 | Unigen, Inc. | Bakuchiol compositions for treatment of post inflammatory hyperpigmentation |
US9295723B2 (en) * | 2013-03-01 | 2016-03-29 | Envy Medical, Inc. | Acne solution |
-
2015
- 2015-04-21 EP EP15782917.7A patent/EP3134078A4/en active Pending
- 2015-04-21 CA CA2946124A patent/CA2946124A1/en active Pending
- 2015-04-21 WO PCT/US2015/026958 patent/WO2015164433A1/en active Application Filing
- 2015-04-21 BR BR112016024528-8A patent/BR112016024528B1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
CA2946124A1 (en) | 2015-10-29 |
BR112016024528B1 (en) | 2023-03-28 |
BR112016024528A2 (en) | 2017-08-15 |
EP3134078A4 (en) | 2017-12-06 |
WO2015164433A1 (en) | 2015-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2961418B1 (en) | Acne solution | |
RU2647479C2 (en) | Composition for face washing as emulsion containing benzoyl peroxide | |
BRPI1004113A2 (en) | benzoyl peroxide composition for skin treatment | |
BR112015010819B1 (en) | topical wash composition and composition use | |
US20150342920A1 (en) | Dermatological compositions comprising at least one retinoid compound, an anti-irritant compound and benzoyl peroxide | |
CN108186679A (en) | A kind of acne-removing composition | |
CN113749986A (en) | Shea butter sensitive skin full-effect repair emulsion and preparation method and application thereof | |
US20180064777A1 (en) | Skin Solution with Solubilized Bakuchiol | |
US20200085959A1 (en) | Cannabinoid and Terpene-Infused Topical Cream | |
CN105581924B (en) | A kind of compound cassia bark oil nanometer emulsion and preparation method thereof | |
US20100183741A1 (en) | Dermatological compositions comprising at least one retinoid compound, an anti-irritant compound and benzoyl peroxide | |
WO2015164433A1 (en) | Acne solution | |
US9433587B2 (en) | Acne solution | |
US20240139269A1 (en) | Skin solution with solubilized bakuchiol | |
EP2588095B1 (en) | Composition for the treatment of acne vulgaris | |
KR20190132197A (en) | Cosmetic composition for use in the treatment and prevention of acne-prone skin | |
JP2014144929A (en) | Composition containing vitamins for preventing or treating acne | |
KR102038366B1 (en) | Cosmetic composition for improving acne skin | |
JP2024516652A (en) | Topical preparations containing benzoyl peroxide and azelaic acid and uses thereof | |
CN118043025A (en) | Sebum-generating-resistant compositions, formulations and uses of the compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20161020 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20171106 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 36/60 20060101ALI20171027BHEP Ipc: A61P 17/10 20060101ALI20171027BHEP Ipc: A61K 31/05 20060101ALI20171027BHEP Ipc: A61K 36/487 20060101AFI20171027BHEP Ipc: A61K 47/00 20060101ALI20171027BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20200909 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230331 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 45/06 20060101ALI20240503BHEP Ipc: A61K 31/203 20060101ALI20240503BHEP Ipc: A61K 31/327 20060101ALI20240503BHEP Ipc: A61K 31/05 20060101ALI20240503BHEP Ipc: A61K 36/60 20060101ALI20240503BHEP Ipc: A61P 17/10 20060101ALI20240503BHEP Ipc: A61K 47/00 20060101ALI20240503BHEP Ipc: A61K 9/00 20060101ALI20240503BHEP Ipc: A61K 36/487 20060101AFI20240503BHEP |
|
INTG | Intention to grant announced |
Effective date: 20240524 |